PVI
CLVS

Pura Vida Investments’s Clovis Oncology, Inc. CLVS Stock Holding History

Pura Vida Investments’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-30,000
Closed -$2.81M – 95
2017
Q2 		$2.81M Buy
+30,000
New +$1.84M 1.12% 34

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Pura Vida Investments's CLVS Position: Q3 2021 in Review

Pura Vida Investments sold out of Clovis Oncology, Inc. (CLVS) in Q3 2021, closing a stake of 97,641 shares — an estimated $566K sold.

Pura Vida Investments first reported a position in CLVS in Q1 2017 and held it in 4 quarters. The position peaked at $6.55M in Q2 2017. 157 funds tracked by Wall St. Rank hold CLVS as of Q3 2021.

  • Pura Vida Investments reported no remaining Clovis Oncology, Inc. position as of Q3 2021 after selling out during the quarter.
  • Pura Vida Investments sold 97,641 Clovis Oncology, Inc. shares in Q3 2021, an estimated $566K.
  • Pura Vida Investments first reported a position in Clovis Oncology, Inc. in Q1 2017 and held it in 4 quarters.
  • Pura Vida Investments's Clovis Oncology, Inc. position peaked at $6.55M in Q2 2017.
  • 157 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2021.

Based on Pura Vida Investments's 13F filing for Q3 2021, filed 15 Nov 2021.